Fifteen dogs with hemangiosarcoma were treated with a combination of vincristine, doxorubicin, and cyclophosphamide after incisional or excisional biopsy. The median survival for all fifteen dogs was 172 days (mean survival = 316 days). The median survival for those dogs with splenic hemangiosarcoma was 145 days (mean survival = 271 days) as compared with previously published median survival times in dogs with splenic hemangiosarcoma treated with surgery alone of 19 to 65 days. Toxicities included neutropenia (11/15), severe gastroenteritis (4/15), cardiotoxicity (3/15), and sepsis (2/15). The authors conclude that vincristine, doxorubicin, and cyclophosphamide chemotherapy may be an efficacious treatment modality in dogs with hemangiosarcoma and is associated with acceptable toxicity. Copyright © 1991, Wiley Blackwell. All rights reserved
CITATION STYLE
Hammer, Ai. S., Couto, C. G., Filppi, J., Getzy, D., & Shank, K. (1991). Efficacy and Toxicity of VAC Chemotherapy (Vincristine, Doxorubicin, and Cyclophosphamide) in Dogs with Hemangiosarcoma. Journal of Veterinary Internal Medicine, 5(3), 160–166. https://doi.org/10.1111/j.1939-1676.1991.tb00943.x
Mendeley helps you to discover research relevant for your work.